• info@heparegenix.com
  • +49 (0)7071 7912810
  • Sitemap
  • Site Notice
  • Privacy Policy
HepaRegeniX GmbH
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • Press
  • Contact
Search
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • Press
  • Contact

HepaRegeniX GmbH kündigt Management-Wechsel an: Dr. Michael Lutz zum neuen CEO/Geschäftsführer benannt

p3889712020-11-18T13:54:23+01:00

Dr. Lutz is an experienced biotech entrepreneur who has spent the last 15 years at executive management positions with several Life Sciences companies which he successfully established...

10/17/2019
By p3889712019, PressemitteilungComments Off
Read more...
Get In Touch
HepaRegeniX GmbH: Logo

HepaRegeniX has successfully discovered and developed several preclinical drug candidates for the treatment of acute and chronic liver diseases.

Get in touch

Phone: +49 (0)7071 7912810
Fax: +49 (0)7071 7912809
E-mail: info@heparegenix.com

Address

HepaRegeniX GmbH
Eisenbahnstraße 63
72072 Tübingen
Germany

© Copyright 2016-2020 HepaRegeniX GmbH. All Rights Reserved.